ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Iodine-125 labeled 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors

Cite this: J. Med. Chem. 1988, 31, 1, 5–7
Publication Date (Print):January 1, 1988
    ACS Legacy Archive

    Article Views





    Other access options

    Note: In lieu of an abstract, this is the article's first page.

    Free first page

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 87 publications.

    1. Richard A. Glennon, Małgorzata Dukat. 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents – A Review. ACS Pharmacology & Translational Science 2024, Article ASAP.
    2. Richard A. Glennon . The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The “Phenylalkylaminome” with a Focus on Selected Drugs of Abuse. Journal of Medicinal Chemistry 2017, 60 (7) , 2605-2628.
    3. Cynthia S. Dowd,, Katharine Herrick-Davis,, Christina Egan,, Ann DuPre,, Carol Smith,, Milt Teitler, and, Richard A. Glennon. 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT2A Partial Agonists. Journal of Medicinal Chemistry 2000, 43 (16) , 3074-3084.
    4. Queenie Xianghong Wang,, Jennifer King, and, Otto Phanstiel IV. An Improved Synthesis of O-Benzoyl Protected Hydroxamates. The Journal of Organic Chemistry 1997, 62 (23) , 8104-8108.
    5. Andrew O. Stewart,, Pramila A. Bhatia,, Jonathan G. Martin,, James B. Summers,, Karen E. Rodriques,, Michael B. Martin,, James H. Holms,, Jimmie L. Moore,, Richard A. Craig,, Teodozyj Kolasa,, James D. Ratajczyk,, Hormoz Mazdiyasni,, Francis A. J. Kerdesky,, Shari L. DeNinno,, Robert G. Maki,, Jennifer B. Bouska,, Patrick R. Young,, Carmine Lanni,, Randy L. Bell,, George W. Carter, and, Clint D. W. Brooks. Structure−Activity Relationships of N-Hydroxyurea 5-Lipoxygenase Inhibitors. Journal of Medicinal Chemistry 1997, 40 (13) , 1955-1968.
    6. Clint D. W. Brooks and, James B. Summers. Modulators of Leukotriene Biosynthesis and Receptor Activation. Journal of Medicinal Chemistry 1996, 39 (14) , 2629-2654.
    7. Ryan H. Gumpper, Bryan L. Roth. Psychedelics: preclinical insights provide directions for future research. Neuropsychopharmacology 2024, 49 (1) , 119-127.
    8. Glen E. Kellogg, Yana Cen, Malgorzata Dukat, Keith C. Ellis, Youzhong Guo, Jiong Li, Aaron E. May, Martin K. Safo, Shijun Zhang, Yan Zhang, Umesh R. Desai. Merging cultures and disciplines to create a drug discovery ecosystem at Virginia commonwealth university: Medicinal chemistry, structural biology, molecular and behavioral pharmacology and computational chemistry. SLAS Discovery 2023, 28 (6) , 255-269.
    9. Reynald Mangeant, Emmanuelle Dubost, Thomas Cailly, Valérie Collot. Radiotracers for the Central Serotoninergic System. Pharmaceuticals 2022, 15 (5) , 571.
    10. Nicholas M. Barnes, Gerard P. Ahern, Carine Becamel, Joël Bockaert, Michael Camilleri, Severine Chaumont-Dubel, Sylvie Claeysen, Kathryn A. Cunningham, Kevin C. Fone, Michael Gershon, Giuseppe Di Giovanni, Nathalie M. Goodfellow, Adam L. Halberstadt, Rachel M. Hartley, Ghérici Hassaine, Katharine Herrick-Davis, Ruud Hovius, Enza Lacivita, Evelyn K. Lambe, Marcello Leopoldo, Finn Olav Levy, Sarah C. R. Lummis, Philippe Marin, Luc Maroteaux, Andrew C. McCreary, David L. Nelson, John F. Neumaier, Adrian Newman-Tancredi, Hugues Nury, Alexander Roberts, Bryan L. Roth, Anne Roumier, Gareth J. Sanger, Milt Teitler, Trevor Sharp, Carlos M. Villalón, Horst Vogel, Stephanie W. Watts, Daniel Hoyer, . International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews 2021, 73 (1) , 310-520.
    11. Pradeep M. Mhaldar, Dattaprasad M. Pore. Envirocat EPZ-10: An Efficient Catalyst for the Synthesis of 1,2,4- Triazolidine-3-thiones. Letters in Organic Chemistry 2020, 17 (4) , 321-326.
    12. Adam S. Hogendorf, Agata Hogendorf, Rafał Kurczab, Grzegorz Satała, Tomasz Lenda, Maria Walczak, Gniewomir Latacz, Jadwiga Handzlik, Katarzyna Kieć-Kononowicz, Joanna M. Wierońska, Monika Woźniak, Paulina Cieślik, Ryszard Bugno, Jakub Staroń, Andrzej J. Bojarski. Low-basicity 5-HT7 Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol. Scientific Reports 2017, 7 (1)
    13. RL Carhart-Harris, DJ Nutt. Serotonin and brain function: a tale of two receptors. Journal of Psychopharmacology 2017, 31 (9) , 1091-1120.
    14. David E. Nichols. Chemistry and Structure–Activity Relationships of Psychedelics. 2017, 1-43.
    15. Rathinam Ramesh, Appaswami Lalitha. PEG-assisted two-component approach for the facile synthesis of 5-aryl-1,2,4-triazolidine-3-thiones under catalyst-free conditions. RSC Advances 2015, 5 (63) , 51188-51192.
    16. Juan F. López-Giménez, M. Teresa Vilaró, José M. Palacios, Guadalupe Mengod. Multiple conformations of 5-HT2A and 5-HT2C receptors in rat brain: an autoradiographic study with [125I](±)DOI. Experimental Brain Research 2013, 230 (4) , 395-406.
    17. Louise M. Paterson, Birgitte R. Kornum, David J. Nutt, Victor W. Pike, Gitte M. Knudsen. 5‐HT radioligands for human brain imaging with PET and SPECT. Medicinal Research Reviews 2013, 33 (1) , 54-111.
    18. V. Kanagarajan, J. Thanusu, M. Gopalakrishnan. Synthesis and in vitro microbiological evaluation of novel 2,4-diaryl-3-azabicyclo[3.3.1]nonan-9,5′-spiro-1′,2′,4′-triazolidine-3′-thiones. Medicinal Chemistry Research 2012, 21 (12) , 3965-3972.
    19. Adam L. Halberstadt, David E. Nichols, Mark A. Geyer. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology 2012, 221 (4) , 709-718.
    20. . Drug Discrimination and Development of Novel Agents and Pharmacological Tools. 2011, 217-233.
    21. V. Kanagarajan, J. Thanusu, M. R. Ezhilarasi, M. Gopalakrishnan. Solvent-free one-pot synthesis, characterization, antibacterial and antifungal activities of novel spiropiperidinyl-1,2,4-triazolidine-3-thiones. Chemistry of Heterocyclic Compounds 2011, 47 (1) , 60-66.
    22. M. Gopalakrishnan, J. Thanusu, V. Kanagarajan, R. Govindaraju. Design, synthesis and in vitro microbiological evaluation of 6,6-dimethyl-7,9-diaryl-1,2,4,8-tetraazaspiro[4.5]decan-3-thiones - A new series of ‘tailor-made’ compounds. Journal of Enzyme Inhibition and Medicinal Chemistry 2009, 24 (2) , 406-412.
    23. M. Gopalakrishnan, V. Kanagarajan, J. Thanusu. Novel one-pot synthesis of 1,2,4-triazolidin-3-thiones comprising piperidine moiety. Green Chemistry Letters and Reviews 2008, 1 (4) , 241-246.
    24. C. N. Filer. Radiolabeling of serotonergic ligands with tritium and iodine-125. Journal of Radioanalytical and Nuclear Chemistry 2008, 277 (3) , 707-714.
    25. David E. Nichols, Stewart P. Frescas, Benjamin R. Chemel, Kenneth S. Rehder, Desong Zhong, Anita H. Lewin. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): A high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorganic & Medicinal Chemistry 2008, 16 (11) , 6116-6123.
    26. M. Locker, J. Bitard, C. Collet, A. Poliard, V. Mutel, J.M. Launay, O. Kellermann. Stepwise control of osteogenic differentiation by 5-HT2B receptor signaling: Nitric oxide production and phospholipase A2 activation. Cellular Signalling 2006, 18 (5) , 628-639.
    27. William A. Wolf, Gerald J. Bieganski, Veronica Guillen, Laurence Mignon. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced “early onset” vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology 2005, 182 (1) , 84-94.
    28. Anil Purohit, Carol Smith, Katharine Herrick-Davis, Milt Teitler. Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs. Psychopharmacology 2005, 179 (2) , 461-469.
    29. C. Ramalingan, S. Balasubramanian, S. Kabilan. Synthesis of 6-Substituted/Unsubstituted- 7,9-diaryl-1,2,4,8-tetraazaspiro[4.5]- decan-3-thiones. Synthetic Communications 2003, 33 (9) , 1443-1448.
    30. Esther Gómez‐Gil, Cristóbal Gastó, Maribel Díaz‐Ricart, Marta Carretero, Manel Salamero, Rosa Catalán, Ginés Escolar. Platelet 5‐HT 2A ‐receptor‐mediated induction of aggregation is not altered in major depression. Human Psychopharmacology: Clinical and Experimental 2002, 17 (8) , 419-424.
    31. Yolanda Zea-Ponce, Lawrence S Kegeles, Ningning Guo, Leonid Raskin, Venkatesalu Bakthavachalam, Marc Laruelle. Pharmacokinetics and brain distribution in non human primate of R(-)[123I]DOI, A 5HT2A/2C serotonin agonist. Nuclear Medicine and Biology 2002, 29 (5) , 575-583.
    32. Hiroki Okada, Motoko Honda, Hideki Ono. Method for Recording Spinal Reflexes in Mice: Effects of Thyrotropin-Releasing Hormone, DOI, Tolperisone and Baclofen on Monosynaptic Spinal Reflex Potentials. Japanese Journal of Pharmacology 2001, 86 (1) , 134-136.
    33. Angus M Shaw, David C Bunton, Tracy Brown, John Irvine, Allan MacDonald. Regulation of sensitivity to 5-hydroxytryptamine in pulmonary supernumerary but not conventional arteries by a 5-HT1D-like receptor. European Journal of Pharmacology 2000, 408 (1) , 69-82.
    34. F. Serres, J.M. Azorin, M. Valli, R. Jeanningros. Datos para un aumento en los receptores 5-HT 2A funcionales de las plaquetas en pacientes deprimidos utilizando el nuevo ligando [ l25 I]-DOI. European psychiatry (Ed. Española) 2000, 7 (5) , 294-303.
    35. Marie-Louise G Wadenberg, Terrence L Sills, Paul J Fletcher, Shitij Kapur. Antipsychoticlike effects of amoxapine, without catalepsy, using the prepulse inhibition of the acoustic startle reflex test in rats. Biological Psychiatry 2000, 47 (7) , 670-676.
    36. F. Serres, J.-M. Azorin, M. Valli, R. Jeanningros. Evidence for an increase in functional platelet 5-HT 2A receptors in depressed patients using the new ligand [ 125 I]-DOI. European Psychiatry 1999, 14 (8) , 451-457.
    37. M.-L.G. Wadenberg, K.A. Young, J.T. Richter, P.B. Hicks. Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 1999, 38 (1) , 151-156.
    38. Albert S. Chang, Dominic M.‐K. Lam. Mechanistic analyses of ion dependences in a high‐affinity human serotonin transport system in transfected murine fibroblast cells. The Journal of Physiology 1998, 510 (3) , 903-913.
    39. Samuel Samnick, Wolfgang Brandau, Gerhard Nölken, H.J. Gerhards, Otmar Schober. Preparation of 8-[3-(4-Fluorobenzoyl)-propyl]-1-(4-[123I]iodobenzoyl)-1,3,8-triazaspiro[4,5]decan-4-one: A novel selective serotonin 5-HT2 receptor agent. Nuclear Medicine and Biology 1997, 24 (4) , 295-303.
    40. George Bollweg, Sheldon Sparber. Ritanserin blocks DOI-altered embryonic motility and posthatch learning in the developing chicken. Pharmacology Biochemistry and Behavior 1996, 55 (3) , 397-403.
    41. T Obradovic, K.M Imel, S.R White. Methylenedioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine. Neuroscience 1996, 74 (2) , 469-481.
    42. Odile Kellermann, Sylvain Loric, Luc Maroteaux, Jean‐Marie Launay. Sequential onset of three 5‐HT receptors during the 5‐hydroxytryptaminergic differentiation of the murine 1C11 cell line. British Journal of Pharmacology 1996, 118 (5) , 1161-1170.
    43. S.B. Sparber, A. Rizzo, B. Berra. Excessive stimulation of Serotonin2 (5-HT2) receptors during late development of chicken embryos causes decreased embryonic motility, interferes with hatching, and induces herniated umbilici. Pharmacology Biochemistry and Behavior 1996, 53 (3) , 603-611.
    44. R. A. Glennon. Classical Hallucinogens. 1996, 343-371.
    45. Marie-Louise Wadenberg. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neuroscience & Biobehavioral Reviews 1996, 20 (2) , 325-339.
    46. Kerstin Uvnäs-Moberg, Viveka Hillegaart, Pawel Alster, Sven Ahlenius. Effects of 5-HT agonists, selective for different receptor subtypes, on oxytocin, CCK, gastrin and somatostatin plasma levels in the rat. Neuropharmacology 1996, 35 (11) , 1635-1640.
    47. Clare J. Watkins, Nigel R. Newberry. Multiple 5‐HT receptors in the guinea‐pig superior cervical ganglion. British Journal of Pharmacology 1996, 117 (1) , 21-28.
    48. Marie-Louise Wadenberg, Sven Ahlenius. Antagonism by the 5-HT2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat. European Journal of Pharmacology 1995, 294 (1) , 247-251.
    49. Ian K. Anderson, Graeme R. Martin, Andrew G. Ramage. Evidence that activation of 5‐HT 2 receptors in the forebrain of anaesthetized cats causes sympathoexcitation. British Journal of Pharmacology 1995, 116 (2) , 1751-1756.
    50. M.-L. Wadenberg, V. Hillegaart. Stimulation of median, but not dorsal, raphe 5-HT1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 1995, 34 (5) , 495-499.
    51. Milton Aillón. Torres, Bruce Cassels, Macros C. Rezende. The Preparation of Potentially Psychoactive β-Alkoxyphenethylamines. Synthetic Communications 1995, 25 (8) , 1239-1247.
    52. P. Mazzola-Pomietto, C. S. Aulakh, K. M. Wozniak, J. L. Hill, D. L. Murphy. Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology 1995, 117 (2) , 193-199.
    53. Lorraine A. Lebel, Jolanta T. Nowakowski, John E. Macor, Carol B. Fox, B. Kenneth Koe. Dopamine uptake inhibitory activity of novel tryptamine 5‐HT 1 receptor ligands. Drug Development Research 1994, 33 (4) , 413-421.
    54. C.S. Aulakh, T. Tolliver, K.M. Wozniak, J.L. Hill, D.L. Murphy. Functional and biochemical evidence for altered serotonergic function in the Fawn-Hooded rat strain. Pharmacology Biochemistry and Behavior 1994, 49 (3) , 615-620.
    55. Doo-Sup Choi, Guillaume Birraux, Jean-Marie Launay, Luc Maroteaux. The human serotonin 5‐HT2B receptor: Pharmacological link between 5‐HT2 and 5‐HT1D receptors. FEBS Letters 1994, 352 (3) , 393-399.
    56. Izhar A. Khan, Peter Thomas. Seasonal and daily variations in the plasma gonadotropin II response to a LHRH analog and serotonin in Atlantic croaker ( Micropogonias undulatus ): Evidence for mediation by 5‐HT 2 receptors. Journal of Experimental Zoology 1994, 269 (6) , 531-537.
    57. G. S. Gadaginamath, A. G. Kamat. Regioselective Friedel-Crafts acetylation of 5-hydroxyindole derivatives: synthesis of 4H-pyranoindol-4-one derivatives. Proceedings / Indian Academy of Sciences 1994, 106 (4) , 857-862.
    58. Christian Waeber, Jose´M. Palacios. Binding sites for 5-hydroxytryptamine-2 receptor agonists are predominantly located in striosomes in the human basal ganglia. Molecular Brain Research 1994, 24 (1-4) , 199-209.
    59. K.B. Thor, S. Nickolaus, C.J. Helke. Autoradiographic localization of 5-hydroxytryptamine1A, 5-hydroxytryptamine1B and 5-hydroxytryptamine1C/2 binding sites in the rat spinal cord. Neuroscience 1993, 55 (1) , 235-252.
    60. Laura Rydelek-Fitzgerald, Brian D. Wilcox, Milt Teitler, John J. Jeffrey. Serotonin-dependent collagenase induction in rat myometrial smooth muscle cells: Mediation by the 5-HT2 receptor. Molecular and Cellular Endocrinology 1993, 91 (1-2) , 67-74.
    61. Charanjit S. Aulakh, James L. Hill, Hakan T. Yoney, Dennis L. Murphy. Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Psychopharmacology 1992, 109 (4) , 444-448.
    62. Sylvain Loric, Jean-Marie Launay, Jean-François Colas, Luc Maroteaux. New mouse 5‐HT2‐like receptor Expression in brain, heart and intestine. FEBS Letters 1992, 312 (2-3) , 203-207.
    63. Christopher W. Kerr, Georgia A. Bishop. The physiological effects of serotonin are mediated by the 5HT1A receptor in the cat's cerebellar cortex. Brain Research 1992, 591 (2) , 253-260.
    64. C.J.G. Done, T. Sharp. Evidence that 5‐HT 2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. British Journal of Pharmacology 1992, 107 (1) , 240-245.
    65. H. Tan, V. Miletic. Diverse actions of 5-hydroxytryptamine on frog spinal dorsal horn neurons in vitro. Neuroscience 1992, 49 (4) , 913-923.
    66. Y.O. Taiwo, J.D. Levine. Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 1992, 48 (2) , 485-490.
    67. B. Kenneth Koe, Lorraine A. Lebel, Carol B. Fox, John E. Macor. Characterization of [ 3 H]CP‐96,501 as a Selective Radioligand for the Serotonin 5‐HT 1B Receptor: Binding Studies in Rat Brain Membranes. Journal of Neurochemistry 1992, 58 (4) , 1268-1276.
    68. Gyorgy Bagdy, Alan F. Sved, Dennis L. Murphy, Katalin Szemeredi. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. European Journal of Pharmacology 1992, 210 (3) , 285-289.
    69. K.C.F. Fone, A.J. Robinson, C.A. Marsden. Characterization of the 5‐HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5‐HT agonists in rats. British Journal of Pharmacology 1991, 103 (2) , 1547-1555.
    70. Janeen M. Hill, Marc P. Kaufman. Intrathecal serotonin attenuates the pressor response to static contraction. Brain Research 1991, 550 (1) , 157-160.
    71. WV Murray, MP Wachter, AM Kasper, DC Argentieri, RJ Capetola, DM Ritchie. Novel 6-oxo-6-naphthylhexanoic acid derivatives with anti-inflammatory and 5-lipoxygenase inhibitory activity. European Journal of Medicinal Chemistry 1991, 26 (2) , 159-166.
    72. Ulderico Freo, Timothy T. Soncrant, Harold W. Holloway, Stanley I. Rapoport. Dose- and time-dependent effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a serotonergic 5-HT2 receptor agonist, on local cerebral glucose metabolism in awake rats. Brain Research 1991, 541 (1) , 63-69.
    73. J. M. Saavedra, A. Himeno. Autoradiographic Studies of 5HT2 Receptors. 1991, 107-113.
    74. Gyorgy Bagdy, Aldo E. Calogero, Katalin Szemeredi, M. Teresa Gomez, Dennis L. Murphy, George P. Chrousos, Philip W. Gold. β-Endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action. Brain Research 1990, 537 (1-2) , 227-232.
    75. G K Reid, S Kargman, P J Vickers, J A Mancini, C Léveillé, D Ethier, D K Miller, J W Gillard, R A Dixon, J F Evans. Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis.. Journal of Biological Chemistry 1990, 265 (32) , 19818-19823.
    76. MILT TEITLER, SIGRUN LEONHARDT, NATHAN M. APPEL, ERROL B. DE SOUZA, RICHARD A. GLENNON. Receptor Pharmacology of MDMA and Related Hallucinogens a. Annals of the New York Academy of Sciences 1990, 600 (1) , 626-638.
    77. D.A. Jackson, S.R. White. Receptor subtypes mediating facilitation by serotonin of excitability of spinal motoneurons. Neuropharmacology 1990, 29 (9) , 787-797.
    78. Richard A. Glennon. Serotonin receptors: Clinical implications. Neuroscience & Biobehavioral Reviews 1990, 14 (1) , 35-47.
    79. Ian K. Wright, Jeni C. Garratt, C.A. Marsden. Effects of a selective 5‐HT 2 agonist, DOI, on 5‐HT neuronal firing in the dorsal raphe nucleus and 5‐HT release and metabolism in the frontal cortex. British Journal of Pharmacology 1990, 99 (2) , 221-222.
    80. Ray W. Fuller. Drugs affecting serotonin neurons. 1990, 85-108.
    81. Michael P. Johnson, Chester A. Mathis, Alexander T. Shulgin, Andrew J. Hoffman, David E. Nichols. [125I]-2-(2,5-Dimethoxy-4-Iodophenyl) aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacology Biochemistry and Behavior 1990, 35 (1) , 211-217.
    82. Hank F. Kung. Radiopharmaceuticals for CNS receptor imaging with SPECT. International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology 1990, 17 (1) , 85-92.
    83. Bernard Sadzot, Jay M. Baraban, Richard A. Glennon, Robert A. Lyon, Sigrun Leonhardt, Chung-Ren Jan, Milt Titeler. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 1989, 98 (4) , 495-499.
    84. Sigrun Leonhardt, Milt Titeler. Serotonin 5‐HT 2 Receptors: Two States Versus Two Subtypes. Journal of Neurochemistry 1989, 53 (1) , 316-318.
    85. C. A. Mathis, A. J. Hoffman, D. E. Nichols, A. T. Shulgin. Synthesis of high specific activity 125 I‐ and 123 I‐labelled enantiomers of 2,5‐dimethoxy‐4‐iodophenylisopropylamine (DOI). Journal of Labelled Compounds and Radiopharmaceuticals 1988, 25 (11) , 1255-1265.
    86. Robert A. Lyon, Milt Titeler. Pharmacology and Biochemistry of the 5-HT2 Receptor. 1988, 59-88.
    87. Richard A. Glennon. Strategies for the Development of Selective Serotonergic Agents. , 91-142.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect